Al-Harris Esraah S, Al-Janabi As Ad A, Al-Toriahi Kaswer M, Yasseen Akeel A
Department of Pathology and Forensic Medicine, Faculty of Medicine, Kufa University, Kufa, Iraq.
Saudi Med J. 2008 Aug;29(8):1099-104.
To assess the significance of vascular endothelial growth factor (VEGF) protein over expression in human breast cancer, and its possible correlation with cell proliferation marker (Ki-67), grade and stage of breast cancer.
We carried out this study at the Department of Pathology, Kufa University, between November 2006 and September 2007. A retrospective study was employed on paraffin-embedded blocks from 52 female patients with breast cancer. A group of 21 patients with benign breast lesions was included for comparison and 14 cases of normal breast tissue as a control group. This investigation designed to employ immunohistochemistry using Avidin-Biotin Complex (ABC) method for detection of both VEGF and Ki-67.
A total of 87 samples was included. Vascular endothelial growth factor immunoexpression was considered as positive in 61.5% of malignant and in 19% of benign breast lesions. No over expression sign has been noticed in normal breast tissue (p<0.005). No significant difference in VEGF over expression among different histological types of breast cancer (p>0.05). Vascular endothelial growth factor immunostaining was positively correlated with Ki-67, grade, stage, lymph node metastasis, and recurrence of breast cancer (p<0.05). No such correlation has been seen when the age of the patients has been considered.
Vascular endothelial growth factor Vascular endothelial growth factor plays an important role in pathogenesis of breast cancer evolution, and supports the evidence of its role in angiogenesis and cell survival. This study recommended that the blocking of VEGF may be a target for blocking angiogenesis and hence improving the efficacy of anti-cancer therapy.
评估血管内皮生长因子（VEGF）蛋白在人类乳腺癌中过表达的意义，及其与细胞增殖标志物（Ki-67）、乳腺癌分级和分期的可能相关性。
我们于2006年11月至2007年9月在库法大学病理科开展了本研究。对52例女性乳腺癌患者的石蜡包埋组织块进行回顾性研究。纳入21例患有乳腺良性病变的患者作为比较组，并选取14例正常乳腺组织作为对照组。本研究旨在采用抗生物素蛋白-生物素复合物（ABC）法免疫组织化学检测VEGF和Ki-67。
共纳入87个样本。血管内皮生长因子免疫表达在61.5%的恶性乳腺病变和19%的良性乳腺病变中被视为阳性。在正常乳腺组织中未发现过表达迹象（p<0.005）。不同组织学类型的乳腺癌之间VEGF过表达无显著差异（p>0.05）。血管内皮生长因子免疫染色与Ki-67、分级、分期、淋巴结转移及乳腺癌复发呈正相关（p<0.05）。在考虑患者年龄时未发现此类相关性。
血管内皮生长因子在乳腺癌发生发展过程中起重要作用，并支持其在血管生成和细胞存活中作用的证据。本研究建议阻断VEGF可能成为阻断血管生成从而提高抗癌治疗疗效的靶点。
